Chimeric Antigen Receptor (CAR) T Cell Therapies Archives

U.S. FDA Approves Kite’s Tecartus

Accelerated Approval, Approvals, CAR-T Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapies, FDA, FDA/Regulatory, Non-Hodgkin Lymphoma, Relapsed or Refractory Mantle Cell Lymphoma (MCL), T-Cells

The U.S. Food and Drug Administration granted accelerated approval to Gilead Company Kite’s Tecartus (brexucabtagene autoleucel, formerly KTE-X19) as the first approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

July 24, 2020/by Business Wire

Astellas buys U.S. biotech firm Xyphos

Acquisitions, Business, Cancer, Chimeric Antigen Receptor (CAR) T Cell Therapies, Deals, Genetic Medicines, Immune Cells, Immuno-oncology, Immunotherapies, Oncology, Product Pipeline, Shares

Astellas Pharma Inc. bought U.S.-based Xyphos Biosciences Inc. to expand the Japanese drugmaker’s immuno-oncology business, a deal worth up to $665 million.

December 26, 2019/by Reuters Health